How have ABIO shares performed in 2024?

ARCA biopharma's stock was trading at $1.70 on January 1st, 2024. Since then, ABIO stock has increased by 91.2% and is now trading at $3.25. View the best growth stocks for 2024 here .

Are investors shorting ARCA biopharma?

ARCA biopharma saw a increase in short interest in March. As of March 31st, there was short interest totaling 195,700 shares, an increase of 6.6% from the March 15th total of 183,600 shares. Based on an average daily trading volume, of 1,340,000 shares, the days-to-cover ratio is presently 0.1 days. Currently, 1.4% of the company's stock are sold short. View ARCA biopharma's Short Interest .

When is ARCA biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, April 22nd 2024. View our ABIO earnings forecast .

How were ARCA biopharma's earnings last quarter?

ARCA biopharma, Inc. (NASDAQ:ABIO) announced its quarterly earnings results on Thursday, February, 1st. The biopharmaceutical company reported ($0.08) EPS for the quarter.

What is Michael R. Bristow's approval rating as ARCA biopharma's CEO?

1 employees have rated ARCA biopharma Chief Executive Officer Michael R. Bristow on Glassdoor.com . Michael R. Bristow has an approval rating of 100% among the company's employees. This puts Michael R. Bristow in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ARCA biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ARCA biopharma investors own include Aurora Cannabis (ACBFF) , MannKind (MNKD) , Bausch Health Companies (BHC) , Biocept (BIOC) , Novavax (NVAX) , AVEO Pharmaceuticals (AVEO) , Gilead Sciences (GILD) , iBio (IBIO) , Nabriva Therapeutics (NBRV) and Synergy Pharmaceuticals (SGYP) .

How do I buy shares of ARCA biopharma?

Shares of ABIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ABIO

ARCA biopharma (ABIO) Stock Price, News & Analysis

→ You’re invited: Biggest crypto event of 2024 (From InvestorPlace) (Ad)

Free ABIO Stock Alerts

$3.25

+0.04 (+1.25%)

(As of 04/18/2024 ET)

Compare

Today's Range: $3.13
▼
$3.32
50-Day Range: $1.60
▼
$3.27
52-Week Range: $1.56
▼
$3.88

Volume: 218,431 shs
Average Volume: 1.18 million shs
Market Capitalization: $47.13 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get ARCA biopharma alerts:

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About ARCA biopharma Stock (NASDAQ:ABIO)

ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

ABIO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ABIO Stock News Headlines

April 16, 2024 | americanbankingnews.com

ARCA biopharma, Inc. (NASDAQ:ABIO) Short Interest Up 6.6% in March

April 12, 2024 | americanbankingnews.com

ARCA biopharma (NASDAQ:ABIO) Coverage Initiated at StockNews.com

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 9, 2024 | prnewswire.com

SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of ARCA Biopharma, Inc. - ABIO

April 5, 2024 | businesswire.com

ARCA BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO

April 3, 2024 | investorplace.com

Why Is ARCA Biopharma (ABIO) Stock Up 85% Today?

April 3, 2024 | prnewswire.com

Shareholder Alert: Ademi LLP investigates whether ARCA biopharma, Inc. has obtained a Fair Price in its transaction with Oruka

April 3, 2024 | marketwatch.com

ARCA Biopharma in Reverse Merger Pact With Oruka Therapeutics

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 3, 2024 | msn.com

FibroGen, Acorda Therapeutics, Enveric Biosciences among healthcare movers

April 3, 2024 | bizjournals.com

New Paragon spinout lands $275M financing — and reverse merger

April 3, 2024 | markets.businessinsider.com

ARCA Biopharma, Oruka Therapeutics To Combine In All-stock Deal - Quick Facts

April 3, 2024 | msn.com

Small-Cap ARCA Biopharma Stock Soars On Merger Pact: The Details

April 3, 2024 | businesswire.com

ABIO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of ARCA Biopharma, Inc. Is Fair to Shareholders

April 3, 2024 | globenewswire.com

ARCA biopharma and Oruka Therapeutics Announce Merger Agreement

April 3, 2024 | globenewswire.com

ARCA biopharma and Oruka Therapeutics Announce Merger Agreement

March 27, 2024 | msn.com

ARCA Sensation Toni Breidinger Divulges Struggles of ‘Imposter’ Feeling in Male-Dominated NASCAR

March 19, 2024 | finance.yahoo.com

Rx Outreach builds first St. Louis community pharmacy in partnership with ARCA to rid barriers, promote health

March 15, 2024 | finance.yahoo.com

ABIO Apr 2024 2.500 call

March 11, 2024 | msn.com

ARCA throws red flag for General Tire 150 at Phoenix due to lightning

February 23, 2024 | benzinga.com

ARCA biopharma Stock (NASDAQ:ABIO) Dividends: History, Yield and Dates

February 18, 2024 | msn.com

Gus Dean wins ARCA 200 at Daytona in overtime after teammate controversy

February 18, 2024 | msn.com

“I Better Not Comment on That”- Marco Andretti Cites “New Guy” Claims as He Refuses to Call Out ARCA Stars Despite Daytona Wreckfest

February 18, 2024 | msn.com

ARCA driver Andy Jankowiak delivers epic quote during Daytona race

February 16, 2024 | news.yahoo.com

Daytona 500: ARCA 200 race moved up to Friday due to inclement weather

February 16, 2024 | msn.com

Former IndyCar regular Marco Andretti forging a new racing path in NASCAR's ARCA Series

February 16, 2024 | usatoday.com

Live updates: Daytona ARCA race moved from Saturday to Friday night after Truck Series race

See More Headlines

Receive ABIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ARCA biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/01/2024
Today: 4/18/2024
Next Earnings (Estimated): 4/22/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Diagnostic substances
Sub-Industry: N/A
Current Symbol: NASDAQ:ABIO
CUSIP: N/A
CIK: 907654
Web: arcabio.com
Phone: (720) 940-2100
Fax: 720-208-9261
Employees: 4
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.37)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-5,340,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -13.80%
Return on Assets: -13.33%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 59.01
Quick Ratio: 59.01

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.89 per share
Price / Book: 1.12

Miscellaneous

Outstanding Shares: 14,500,000
Free Float: 10,020,000
Market Cap: $47.13 million
Optionable: Optionable
Beta: 1.17

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Dr. Michael R. Bristow M.D. (Age 79)
Ph.D., Co-Founder, President, CEO & Director
Comp: $358.8k
Mr. C. Jeffrey Dekker CPA (Age 59)
CFO, Treasurer & Company Secretary
Comp: $323.07k
Mr. Thomas A. Keuer (Age 65)
Chief Operating Officer
Comp: $400.8k

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ABIO Stock Analysis - Frequently Asked Questions

How have ABIO shares performed in 2024?: ARCA biopharma's stock was trading at $1.70 on January 1st, 2024. Since then, ABIO stock has increased by 91.2% and is now trading at $3.25.
View the best growth stocks for 2024 here.
Are investors shorting ARCA biopharma?: ARCA biopharma saw a increase in short interest in March. As of March 31st, there was short interest totaling 195,700 shares, an increase of 6.6% from the March 15th total of 183,600 shares. Based on an average daily trading volume, of 1,340,000 shares, the days-to-cover ratio is presently 0.1 days. Currently, 1.4% of the company's stock are sold short.
View ARCA biopharma's Short Interest.
When is ARCA biopharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, April 22nd 2024.
View our ABIO earnings forecast.
How were ARCA biopharma's earnings last quarter?: ARCA biopharma, Inc. (NASDAQ:ABIO) announced its quarterly earnings results on Thursday, February, 1st. The biopharmaceutical company reported ($0.08) EPS for the quarter.

What is Michael R. Bristow's approval rating as ARCA biopharma's CEO?: 1 employees have rated ARCA biopharma Chief Executive Officer Michael R. Bristow on Glassdoor.com. Michael R. Bristow has an approval rating of 100% among the company's employees. This puts Michael R. Bristow in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of ARCA biopharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ARCA biopharma investors own include Aurora Cannabis (ACBFF), MannKind (MNKD), Bausch Health Companies (BHC), Biocept (BIOC), Novavax (NVAX), AVEO Pharmaceuticals (AVEO), Gilead Sciences (GILD), iBio (IBIO), Nabriva Therapeutics (NBRV) and Synergy Pharmaceuticals (SGYP).
How do I buy shares of ARCA biopharma?: Shares of ABIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ABIO) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

ARCA biopharma (ABIO) Stock Price, News & Analysis

About ARCA biopharma Stock (NASDAQ:ABIO)

ABIO Stock Price History

ABIO Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

ABIO Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info